

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

Willingness to vaccinate against COVID-19 in the US:
Longitudinal evidence from a nationally representative sample of adults from April–
October 2020

Michael Daly*¹ PhD & Eric Robinson² PhD

¹Department of Psychology, Maynooth University, Co. Kildare, Ireland

² Institute of Population Health Sciences, University of Liverpool, Liverpool, United
Kingdom

* Corresponding author: Michael Daly

Address correspondence to:

Michael Daly Ph.D.
Department of Psychology
1.1.7 Education House
Maynooth University
Maynooth
Ireland
Tel: (01) 474 7742
Email: Michael.A.Daly@mu.ie

Word count: 2508

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Abstract

Introduction: Vaccines against COVID-19 have been developed in unprecedented time. However, the effectiveness of any vaccine is dictated by the proportion of the population willing to be vaccinated. In this observational population-based study we examined intentions to be vaccinated against COVID-19 over the course of the pandemic.

Methods: We analyzed longitudinal data from a nationally representative sample of 7,547 US adults enrolled in the Understanding America Study (UAS). Participants reporting being willing, undecided and unwilling to get vaccinated against coronavirus across 13 assessments conducted from April-October, 2020. Public attitudes to vaccination against the coronavirus were also assessed.

Results: Willingness to vaccinate declined from 71% in April to 53.6% in October. This was explained by an increase in the percentage of participants undecided about vaccinating (from 10.5% to 14.4%) and the portion of the sample unwilling to vaccinate (from 18.5% to 32%). The population subgroups most likely to be undecided/unwilling to vaccinate were those without a degree (undecided: RRR=2.47, 95% CI: 2.04-3.00; unwilling: RRR=1.92, 95% CI: 1.67-2.20), Black participants (undecided: RRR=2.18, 95% CI: 1.73-2.74; unwilling: RRR=1.98, 95% CI: 1.63-2.42), and females (undecided: RRR=1.41, 95% CI: 1.20-1.65; unwilling: RRR=1.29, 95% CI: 1.14-1.46). Those aged 65+, those on high incomes, and other race/ethnicity participants were least likely to be undecided or unwilling to vaccinate. Concerns about potential side effects of a vaccine were common.

Conclusions: Intentions to be vaccinated against coronavirus have declined rapidly during the pandemic and close to half of Americans are undecided or unwilling to be vaccinated.

48 **Declarations of interest:** ER has previously received funding from Unilever and the
49 American Beverage Association for unrelated research.

50 **Financial disclosures:** No financial disclosures were reported by the authors of this paper.

51 **Funding statement:** Unfunded research.

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69 INTRODUCTION

70 As of November, 2020 the COVID-19 pandemic has been responsible for more than 1.3
71 million deaths worldwide¹. Potential vaccines against COVID-19 have been developed in
72 unprecedented time and early findings suggest there are multiple candidate vaccines that may
73 protect against infection and be suitable for mass roll out in the near future^{2,3}. However, the
74 overall effectiveness of any vaccine is dictated, at least in part, by the proportion of the
75 population willing to be vaccinated. Simulation studies suggest at least three quarters of the
76 population may need to be vaccinated to extinguish the ongoing coronavirus pandemic^{4,5}.

77

78 During the early stages of the pandemic (March-June), studies of small samples of European
79 and Australian adults suggested that the majority of people surveyed reported that they would
80 be vaccinated when a widely available vaccine was available⁶⁻⁷. Similarly, a nationally
81 representative study of adults in China conducted in March found that 9 out of 10 would
82 accept a vaccine when available⁸. US studies conducted early in the pandemic found that
83 between 58% and 86% of adults reported they were likely to be vaccinated against COVID-
84 19^{6,9-11}.

85

86 However, the rise of ‘fake news’ during the pandemic has been widely acknowledged^{11,12} and
87 widespread misinformation about the pandemic may have been damaging to public uptake of
88 measures designed to reduce the spread of the virus (e.g. mask-wearing, social distancing)
89 and willingness to vaccinate^{10,13,14}. In addition, because the speed at which coronavirus
90 vaccines have been developed has been unprecedented and this has been widely reported^{2,3},
91 this may have made the general public more hesitant about accepting a vaccine when
92 available^{15,16}. Furthermore, research indicates that in some countries public trust in
93 government handling of the COVID-19 crisis has been negatively affected¹⁷ and this too may

94 have detrimentally affected intentions to follow public health guidance.

95

96 COVID-19 has had a disproportionately large impact on ethnic minorities¹⁸ and groups from

97 lower socioeconomic backgrounds¹⁹ and as infections will likely continue to be socially

98 patterned, understanding whether population demographics determine willingness to

99 vaccinate will also be important. For example, research examining previous influenza

100 vaccination programmes has found that vaccination intentions and uptake are reduced among

101 more disadvantaged groups^{20,21}. Initial research examining coronavirus vaccination intentions

102 has produced mixed findings on the role of demographic predictors, which may be due to a

103 reliance to date on relatively small and non-representative samples to examine population

104 subgroup differences^{9,10,22}.

105

106 At present, there is a lack of up-to-date estimates of the proportion of the general population

107 that would be willing to use a vaccine when available and it is unclear whether estimates of

108 vaccination uptake collected much earlier in the pandemic have changed over time. It will be

109 also important to understand whether intentions to vaccinate are socially patterned and more

110 or less likely in specific population sub-groups, in order for public health messages to be

111 directed at those who are least likely to vaccinate^{15,16}. In the present research we therefore

112 made use of data from the Understanding America Study (UAS), a large nationally

113 representative panel of US adults who have reported their vaccine intentions on thirteen

114 occasions from the outbreak of the pandemic through to October, 2020.

115

116

117

118 **METHODS**

119 **Study design and participants**

120 This study utilized data collected as part of the Understanding America Study (UAS), a
121 nationally representative longitudinal study of adults aged 18 and over. The UAS is a
122 probability-based sample recruited via address-based sampling from the US Postal Service
123 Computerized Delivery Sequence file containing all US postal addresses²³. Participants
124 complete surveys online and those without internet access are provided with tablet computers
125 and internet access. Of 8547 UAS participants eligible to take part in the COVID-19 tracking
126 study, 7547 participated and provided data across 13 waves of assessment conducted every
127 two weeks between April 1st and October 31st, 2020²⁴.

128
129 In total, participants provided 80,060 observations across the 13 survey waves (average
130 response rate of 81.6% among COVID tracking study participants). A small portion (2%) of
131 observations were omitted because they were submitted after October 31st or were missing
132 vaccination intentions or covariate data leaving a total of 78,453 observations (10.4 per
133 participant). The UAS weights were applied to adjust for unequal probabilities of selection
134 into the UAS. Post-stratification weights were also incorporated to provide a correction for
135 non-response by aligning each survey wave with the distribution of demographic
136 characteristics of the US population²⁵.

137

138 **Measures**

139 In each survey wave participants indicated how likely there were to get vaccinated for
140 coronavirus when a vaccine becomes available to the public on a five-point scale. Participants
141 were classified as either: (1) Undecided (responses of ‘unsure’), (2) Unwilling to vaccinate

142 (responses of somewhat or very *unlikely* to vaccinate), or (3) Willing to vaccinate (responses
143 of somewhat or very *likely* to vaccinate).

144
145 Vaccination intentions were predicted by month of survey (April, May, June, July, August,
146 September, October) and a set of demographic variables: age (coded as 18-34, 35-44, 50-64,
147 65+), sex (coded as male, female), race/ethnicity (White, Hispanic, Black, Other
148 race/ethnicity), household income (\leq \$40,00/\$40,000–\$100,000/ \geq \$100,000 gross per annum),
149 college degree (vs. none), and the presence of a chronic health condition (present vs. not
150 present). Specifically, participants indicated whether they had been diagnosed with the
151 following conditions: diabetes, cancer, heart disease, kidney disease, asthma, chronic lung
152 disease, an autoimmune disease.

153
154 Participants also reported their level of agreement (from 1 = strongly disagree, to 4 = strongly
155 agree) with nine items assessing their attitudes towards a potential vaccine (see Table 3 for
156 items in full) in late October (14th-31st). Questions assessed participant beliefs that the
157 COVID vaccine would be beneficial, important for personal and community health, and a
158 good way to protect from coronavirus disease. Participants also indicated whether they
159 agreed approved vaccines would be effective and whether they were concerned about the lack
160 of long-term follow-up information and potential side effect of a COVID vaccine were
161 assessed (e.g. “I think the COVID-19 vaccine might cause lasting health problems for me.”).

162 163 **Statistical analysis**

164 First, we examined trends in vaccinate intentions over the period of the study by comparing
165 the prevalence of willingness/undecided/unwillingness to vaccinate in April and October,
166 2020. To estimate the statistical significance of time trends we used multinomial logistic

167 regression analysis with robust standard errors clustered at the individual-level. Those
168 willing to vaccinate were compared to: (i) those undecided on vaccination, and (ii) those
169 unwilling to vaccinate. A series of multinomial logistic regressions were run to identify if the
170 relative risk of being undecided or unwilling to vaccinate increased from April to October for
171 the overall sample and each population subgroup examined. This model contrasts the natural
172 log [Pr(Willing to vaccinate)/Pr(Unwilling to vaccinate)] and natural log [Pr(Undecided on
173 vaccination)/Pr(Unwilling to vaccinate)] estimates across different demographic groups to
174 ascertain relative risk ratios (RRR).

175
176 Next, multinomial logistic regression was used to estimate the extent to which survey month
177 and different demographic factors predicted vaccination intentions. A single adjusted analysis
178 was used to estimate the independent effect of each predictor variable (i.e. month of survey,
179 age, sex, race/ethnicity, educational attainment, income, presence of a chronic condition)
180 controlling for all others. In addition, we tested a separate model where interactions between
181 survey month and participant demographics were added to our main model to test whether
182 changes in vaccination intentions over time differed systematically between demographic
183 groups.

184
185 All analyses incorporated the UAS sampling weights to generate nationally representative
186 estimates. RRRs and 95% CIs were estimated using the Stata version 15 (Statacorp).

187

188

189

190

191 **RESULTS**

192 Participants were aged 47.2 (SD = 16.6) years on average, 52.1% were female, 34.2% had a
193 college degree, and 64.1% were White, 17.8% Hispanic, 12.2% Black, and 5.9% Other
194 race/ethnicity (see Table 1). On average, willingness to vaccinate declined from 71% in April
195 to 53.6% in October. This was explained by an increase in the percentage of participants
196 undecided about vaccinating against COVID-19 (from 10.5% to 14.4%) and the portion of
197 the sample unwilling to vaccinate (from 18.5% to 32%), as shown in Table 1. A decrease in
198 the willingness to vaccinate against COVID-19 between April and October was evident
199 across all population subgroups examined (Table 1).

200

201 An unadjusted multinomial logistic regression analysis confirmed that from April to October,
202 2020 there was a statistically significant higher risk of being undecided (RRR = 1.82, 95%
203 CI: 1.62-2.05) or unwilling (RRR = 2.29, 95% CI: 2.11-2.48) to be vaccinated versus being
204 willing to get vaccinated (see Table S1). Unadjusted multinomial logistic regression analyses
205 also showed that all population subgroups were more likely to be undecided or unwilling to
206 vaccinate in October compared to April (Table S1). There was also an over 2-fold higher
207 relative likelihood of being undecided or unwilling to get the COVID-19 vaccine in October
208 compared to April, 2020 (undecided: RRR = 2.03, 95% CI: 1.79-2.29; unwilling: RRR =
209 2.47, 95% CI: 2.27-2.68) in a fully adjusted model that included controls for participant
210 demographic factors and the presence of chronic illness (Table 2). An examination of month-
211 to-month changes confirmed that the likelihood of being undecided or unwilling to vaccinate
212 (versus being willing to vaccinate) increased in a graded fashion from April to October, as
213 shown in Table 2 and illustrated in Figure 1.

214

215 When all observations from 13 survey waves were examined, those without a college degree
216 were at elevated relative risk of being undecided or unwilling to vaccinate (undecided: RRR
217 = 2.47, 95% CI: 2.04-3.00; unwilling: RRR = 1.92, 95% CI: 1.67-2.20), as were Black
218 participants (undecided: RRR = 2.18, 95% CI: 1.73-2.74; unwilling: RRR = 1.98, 95% CI:
219 1.63-2.42) and females (undecided: RRR = 1.41, 95% CI: 1.20-1.65; unwilling: RRR = 1.29,
220 95% CI: 1.14-1.46). In contrast, a reduced relative risk of being undecided or unwilling to
221 vaccinate was found among those aged 65+ (undecided: RRR = 0.49, 95% CI: 0.38-0.63
222 unwilling: RRR=0.61, 95% CI: 0.51-0.74), those on high household incomes (undecided:
223 RRR = 0.40, 95% CI: 0.32-0.50; unwilling: RRR=0.52, 95% CI: 0.39-0.71), and other
224 race/ethnicity participants (undecided: RRR = 0.57, 95% CI: 0.40-0.82; unwilling:
225 RRR=0.52, 95% CI: 0.39-0.71).

226

227 An examination of the interactions between survey month and individual demographic
228 characteristics did not yield evidence for systematic differences in changes in vaccination
229 intentions over time between demographic groups.

230

231 Finally, we examined attitudes towards the vaccine reported between October 14-31, 2020.
232 The majority of the sample (70-80%) agreed that the COVID vaccine would be personally
233 beneficial, important for personal and community health, a good way to protect from
234 coronavirus disease, and effective if approved by the U.S. Food and Drug Administration
235 (FDA) or the Centre for Disease Control and Prevention (CDC; see Table 3). However,
236 responses differed markedly between those willing and unwilling to be vaccinated. For
237 example, while 92% of those who were willing to be vaccinated agreed that the vaccine
238 would be effective if approved by the FDA or CDC, only 43% of those unwilling to be

239 vaccinated agreed. In the overall sample it was common for participants to report concerns
240 over the vaccine and 69.7% agreed they were concerned about serious side effects of the
241 vaccine. Forty-four % agreed the vaccine might cause lasting health problems for them.
242 However, such concerns were more prevalent among those unwilling to be vaccinated. For
243 example, 65% of this group were concerned about lasting health problems resulting from the
244 vaccine compared to 27% of those willing to be vaccinated.

245

246 **DISCUSSION**

247 In a large nationally representative sample of US adults, intentions to be vaccinated against
248 COVID-19 have declined from a high of 71% of the population in April to close to only 54%
249 reporting being willing to vaccinate in October, 2020. Reporting being undecided or
250 unwilling to vaccinate was more likely among those with lower levels of education and
251 income, females, Black (African American) and younger adults. Concerns about the vaccine
252 causing long lasting health problems and uncertainty about the benefits of the vaccine were
253 also common.

254

255 Based on estimates that vaccination coverage of close to 75% may be required to vaccinate to
256 eradicate coronavirus^{4,5,10,26}, our estimates that close to 50% of the population may be willing
257 to vaccinate are concerning. It will now be critical to better understand the reasons why a
258 large proportion of the population are sceptical about vaccination against COVID-19. Public
259 concerns about the safety of vaccines may be an important driver of the increase in the
260 proportion of the population reporting being unsure or explicitly stating they will not
261 vaccinate¹⁰.

262 In line with this, 70% of the present sample reported being concerned about serious side
263 effects of the vaccine and 44% believed that a vaccine might cause lasting health problems
264 for them. To some extent these concerns are to be expected given the unprecedented speed at
265 which vaccines have been developed^{2,3} and current lack of information on long-term safety of
266 candidate vaccines. However, the rise of anti-vaccination misinformation (e.g. misleading
267 healthcare information, conspiracy theories) may also have played a role in explaining this
268 increase^{11-14,26}. It will therefore be critical that accurate safety information is widely and
269 transparently communicated by trusted sources to promote confidence in the scientific
270 decision-making underpinning the approval of COVID-19 vaccines^{16,21}.

271
272 It will also be important to address social inequalities in vaccination intentions^{20,21}, and to
273 ensure widespread uptake of effective COVID-19 vaccines. In the present study, willingness
274 to vaccinate was strikingly lower among more disadvantaged groups (e.g. African Americans,
275 those with lower income and education levels) and these groups have already been
276 disproportionately affected by COVID-19^{18,19}. Previous research on influenza vaccines also
277 suggests that access issues may prevent minority and disadvantaged groups from being
278 vaccinated^{21,27}. It will therefore be important to identify strategies to reduce social
279 inequalities in both vaccination intentions and opportunities to vaccinate²⁰.

280
281 Strengths of the present research include the use of a large probability-based nationally
282 representative sample of adults allowing generalizations to be made to the population. The
283 current study also moves beyond prior research by including a high frequency longitudinal
284 assessment of vaccination intentions throughout the pandemic. In addition, participant
285 concerns and perceptions of the benefits of a potential vaccine were assessed to shed light on
286 potential reasons for low willingness to vaccinate.

287 Limitations are our reliance on self-reported intentions and the lack of detailed assessment of
288 factors that may explain why vaccination intentions have declined over time in the US.
289 However, in advance of the deployment of a COVID vaccine it is necessary to rely on
290 intention-based measures which have been shown to predict vaccination behavior²⁷. Further,
291 intentions are malleable and represent a target for evidence-based approaches aiming to
292 increase the proportion of the population that are willing to vaccinate²⁸. This now represents
293 an urgent public health priority to minimize further loss of life due to the COVID-19
294 pandemic²⁹. Finally, studies tracking vaccination attitudes including perceived health benefits
295 and side-effects of vaccination, long-term health concerns, and the role of misinformation are
296 now needed to provide an in-depth understanding of the drivers of changes in vaccine
297 intentions.

298

299 **CONCLUSION**

300 Intentions to be vaccinated against coronavirus have declined rapidly during the pandemic
301 and close to half of Americans are undecided or unwilling to be vaccinated. This reduced
302 willingness to vaccinate may undermine the pandemic response and the public health benefits
303 of an effective vaccine.

304

305

306

307

308

309

310 **Author Contributions:** Dr Daly had full access to the study data and takes responsibility for
311 the integrity of the data and accuracy of the data analysis.

312 *Concept and design:* All authors.

313 *Acquisition, analysis, or interpretation of data:* All authors.

314 *Drafting of the manuscript:* All authors.

315 *Critical revision of the manuscript for important intellectual content:* All authors.

316 *Statistical analysis:* Daly.

317 **Acknowledgements:** The project described in this paper relies on data from survey(s)
318 administered by the Understanding America Study, which is maintained by the Center for
319 Economic and Social Research (CESR) at the University of Southern California. The content
320 of this paper is solely the responsibility of the authors and does not necessarily represent the
321 official views of USC or UAS. The collection of the UAS COVID-19 tracking data is
322 supported in part by the Bill & Melinda Gates Foundation and by grant U01AG054580 from
323 the National Institute on Aging. However, these organizations bear no responsibility for the
324 analysis or interpretation of the data.

325

326

327

328

329

330

331

332

333

334

335 **REFERENCES**

- 336 1. World Health Organization (WHO). *WHO COVID-19 Weekly Epidemiological Update*.
337 2020: [https://www.who.int/publications/m/item/weekly-epidemiological-update---24-](https://www.who.int/publications/m/item/weekly-epidemiological-update---24-november-2020)
338 november-2020
- 339 2. Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 vaccines at pandemic
340 speed. *N Engl J Med*. 2020;382(21):1969-73.
- 341 3. Callaway E. COVID vaccine excitement builds as Moderna reports third positive result.
342 *Nature*. 2020;587(7834):337-338
- 343 4. Bartsch SM, O'Shea KJ, Ferguson MC, et al. Vaccine efficacy needed for a COVID-19
344 coronavirus vaccine to prevent or stop an epidemic as the sole intervention. *Am J Prev*
345 *Med*. 2020;59(4):493-503.
- 346 5. Iboi EA, Ngonghala CN, Gumel AB. Will an imperfect vaccine curtail the COVID-19
347 pandemic in the U.S.? *Infect Dis Model*. 2020;5:510-524.
- 348 6. Lazarus, J.V., Ratzan, S.C., Palayew, A. et al. A global survey of potential acceptance of a
349 COVID-19 vaccine. *Nat Med*. 2020. <https://doi.org/10.1038/s41591-020-1124-9>
- 350 7. Dodd RH, Cvejic E, Bonner C, et al. Willingness to vaccinate against COVID-19 in
351 Australia. *Lancet Infect Dis*. 2020:S1473-3099(20)30559-4. doi: 10.1016/S1473-
352 3099(20)30559-4
- 353 8. Wang J, Jing R, Lai X et al. Acceptance of COVID-19 vaccination during the COVID-19
354 pandemic in China. *Vaccines*. 2020, 8, 482. doi:10.3390/vaccines8030482
- 355 9. Taylor S, Landry CA, Paluszek MM, Groenewoud R, Rachor GS, Asmundson GJ. A
356 proactive approach for managing COVID-19: The importance of understanding the
357 motivational roots of vaccination hesitancy for SARS-CoV2. *Front Psychol*.
358 2020;11:2890. doi.org/10.3389/fpsyg.2020.575950

- 359 10. Fisher KA, Bloomstone SJ, Walder J, et al. Attitudes toward a potential SARS-CoV-2
360 vaccine: A survey of U.S. adults. *Ann Intern Med.* 2020. doi: 10.7326/M20-3569
- 361 11. Romer D, Jamieson KH. Conspiracy theories as barriers to controlling the spread of
362 COVID-19 in the US. *Soc Sci Med.* 2020;263:113356. doi.org/10.1016/
363 j.socscimed.2020.113356
- 364 12. Kata A. A postmodern Pandora's box: Anti-vaccination misinformation on the Internet.
365 *Vaccine.* 2010;28(7):1709-16
- 366 13. Roozenbeek J, Schneider CR, Dryhurst S, et al. Susceptibility to misinformation about
367 COVID-19 around the world. *R Soc Open Sci.* 2020;7(10):201199.
- 368 14. Allcott H, Boxell L, Conway J. Polarization and public health: Partisan differences in
369 social distancing during the coronavirus pandemic. *J Public Econ* 2020:
370 doi.org/10.1016/j.jpubeco.2020.104254
- 371 15. Neumann-Böhme S, Varghese NE, Sabat I, et al. Once we have it, will we use it? A
372 European survey on willingness to be vaccinated against COVID-19. *Eur J Health Econ.*
373 2020;21(7):977-82.
- 374 16. Bauchner H, Malani PN, Sharfstein J. Reassuring the public and clinical community
375 about the scientific review and approval of a COVID-19 vaccine. *JAMA.*
376 2020;324(13):1296-7.
- 377 17. Fancourt D, Steptoe A, Wright L. The Cummings effect: politics, trust, and behaviours
378 during the COVID-19 pandemic. *Lancet.* 2020;396(10249):464-5.
- 379 18. Townsend MJ, Kyle TK, Stanford FC. Outcomes of COVID-19: disparities in obesity
380 and by ethnicity/race. *Int J Obes.* 2020;44,1807-09.
- 381 19. Lamb MR, Kandula S, Shaman J. Differential COVID-19 case positivity in New York
382 City neighborhoods: Socioeconomic factors and mobility. *Influenza Other Respir*
383 *Viruses.* 2020; doi.org/10.1111/irv.12816

- 384 20. Endrich MM, Blank PR, Szucs TD. Influenza vaccination uptake and socioeconomic
385 determinants in 11 European countries. *Vaccine*. 2009;27(30):4018-24.
386 doi.org/10.1016/j.vaccine.2009.04.029
- 387 21. Galarce EM, Minsky S, Viswanath K. Socioeconomic status, demographics, beliefs and
388 A (H1N1) vaccine uptake in the United States. *Vaccine*. 2011;29(32):5284-9.
- 389 22. Reiter PL, Pennell ML, Katz ML. Acceptability of a COVID-19 vaccine among adults in
390 the United States: How many people would get vaccinated? *Vaccine*. 2020;38(42):6500-
391 7.
- 392 23. Alattar L, Messel M, Rogofsky D. An introduction to the Understanding America Study
393 internet panel. *Soc Sec Bull*. 2018;78(2):13-28.
394 <https://www.ssa.gov/policy/docs/ssb/v78n2/v78n2p13.html>.
- 395 24. Kapteyn A, Angrisani M, Bennett D, et al. Tracking the effect of the COVID-19
396 pandemic on the lives of American households. *Surv Res Methods*. 2020;14(2):179-86.
397 <https://doi.org/10.18148/srm/2020.v14i2.7737>
- 398 25. Angrisani M, Kapteyn A, Meijer E et al. Sampling and weighting the Understanding
399 America Study. *WP No. 2019-004*. 2019. University of Southern California, Center for
400 Economic and Social Research. <https://doi.org/10.2139/ssrn.3502405>
- 401 26. Mills M, Rahal C, Brazel D et al. *Rapid review: COVID-19 vaccine deployment:
402 Behaviour, ethics, misinformation and policy strategies*. 2020. The Royal Society.
403 <https://royalsociety.org/-/media/policy/projects/set-c/set-c-vaccine-deployment.pdf>
- 404 27. Schmid P, Rauber D, Betsch C. Barriers of influenza vaccination intention and behavior—a
405 systematic review of influenza vaccine hesitancy, 2005–2016. *PLOS One*.
406 2017;12(1):e0170550.

- 407 28. Wegwarth O, Kurzenhäuser-Carstens S, Gigerenzer G. Overcoming the knowledge–
408 behavior gap: the effect of evidence-based HPV vaccination leaflets on understanding,
409 intention, and actual vaccination decision. *Vaccine*. 2014;32(12):1388-93.
- 410 29. Paul E, Steptoe A, Fancourt D. Anti-vaccine attitudes and risk factors for not agreeing to
411 vaccination against COVID-19 amongst 32,361 UK adults: Implications for public health
412 communications. *SSRN*. 2020. <http://dx.doi.org/10.2139/ssrn.3716874>

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432 Table 1. Sample characteristics of participants in the Understanding American Study
433 (UAS; N = 7,547, Obs. = 78,453) and vaccination intentions in April and October, 2020.

		Willing to vaccinate ^a		Undecided on vaccination ^a		Unwilling to vaccinate ^a	
Survey month		April	October	April	October	April	October
Variable	Sample size (%)	%	%	%	%	%	%
Overall sample		71.0	53.6	10.5	14.4	18.5	32.0
Age group							
18-34	2024 (26.8)	65.6	47.2	12.9	16.2	21.5	36.6
35-49	2305 (30.5)	67.5	49.6	11.5	15.5	21.0	34.9
50-64	1832 (24.3)	73.1	54.2	10.6	15.1	16.3	30.7
65+	1387 (18.4)	79.9	65.9	6.0	10.0	14.1	24.0
Sex							
Male	3613 (47.9)	75.1	60.0	8.2	11.7	16.7	28.3
Female	3934 (52.1)	67.2	47.6	12.7	17.0	20.1	35.4
Race/ethnicity							
White	4840 (64.1)	74.7	57.3	8.6	13.0	16.7	29.7
Hispanic	1345 (17.8)	67.4	47.5	12.2	16.2	20.5	36.3
Black	917 (12.2)	47.9	33.8	22.0	21.8	30.1	44.3
Other race/ ethnicity	445 (5.9)	86.5	68.6	4.0	11.1	9.5	20.4
Education							
No degree	4970 (65.8)	65.7	45.1	13.1	18.2	21.2	36.7
College degree	2578 (34.2)	81.4	68.9	5.4	7.8	13.2	23.4
Income level ^b							
Low income	2884 (38.2)	64.1	43.6	15.6	21.4	20.3	35.0
Middle income	3007 (40.4)	71.6	55.0	8.6	12.1	19.8	33.0
High income ^b	1656 (21.9)	81.1	66.9	5.6	7.8	13.3	25.4
Chronic condition ^c							
No	5060 (67.0)	69.5	52.5	10.6	14.2	19.9	33.4
Yes	2446 (32.4)	74.1	55.8	10.3	14.9	15.6	29.2

434 Note: Weighted demographic characteristics and vaccination intentions are presented.

435 ^a Based-on responses to the question “How likely are you to get vaccinated for coronavirus
436 once a vaccine is available to the public?”

437 ^b Households earning less than \$40,000 a year classified as low income, those earning
438 \$40,000 -\$100,000 middle income, and those above this threshold as high-income.

439 ^c Diagnosed with any of the following: diabetes, cancer, heart disease, kidney disease,
440 asthma, chronic lung disease, an autoimmune disease. 41 participants did not provide chronic
441 illness data.

442 Table 2. Results of adjusted multinomial logistic regression analyses examining
443 demographic predictors and temporal changes in indecision and unwillingness to vaccinate
444 against COVID-19 in the United States (N = 7,547, Obs. = 78,453).

Variable	Undecided on vaccination		Unwilling to vaccinate	
	RRR ^a	(95% CI)	RRR ^a	(95% CI)
Month (ref. is April)				
May	1.27***	(1.15, 1.41)	1.54***	(1.44, 1.66)
June	1.34***	(1.18, 1.52)	1.65***	(1.51, 1.80)
July	1.47***	(1.30, 1.67)	1.76***	(1.62, 1.91)
August	1.50***	(1.33, 1.68)	1.97***	(1.82, 2.13)
September	1.92***	(1.70, 2.16)	2.34***	(2.16, 2.55)
October	2.03***	(1.79, 2.29)	2.47***	(2.27, 2.68)
Age group (ref. is 18-34)				
35-49	1.07	(0.87, 1.33)	1.02	(0.85, 1.21)
50-64	0.88	(0.71, 1.09)	0.81*	(0.68, 0.97)
65+	0.49***	(0.38, 0.63)	0.61***	(0.51, 0.74)
Sex (ref. is male)				
Female	1.41***	(1.20, 1.65)	1.29***	(1.14, 1.46)
Race/ethnicity (ref. is White)				
Hispanic	1.05	(0.82, 1.35)	1.02	(0.84, 1.25)
Black	2.18***	(1.73, 2.74)	1.98***	(1.63, 2.42)
Other race/ ethnicity	0.57**	(0.40, 0.82)	0.52***	(0.39, 0.71)
Education (ref. is degree)				
No degree	2.47***	(2.04, 3.00)	1.92***	(1.67, 2.20)
Income level (ref. is low income) ^b				
Middle income	0.58***	(0.48, 0.69)	1.01	(0.88, 1.16)
High income	0.40***	(0.32, 0.50)	0.75**	(0.63, 0.90)
Chronic condition ^c	0.96	(0.81, 1.14)	0.84*	(0.74, 0.96)

445 ^a Estimates are relative risk ratios derived from multinomial logistic regression with standard
446 errors adjusted for clustering at the individual-level and controlling for all characteristics
447 presented. For all analyses “willing to vaccinate” was the outcome reference group.

448 ^b Households earning less than \$40,000 a year classified as low income, those earning
449 \$40,000 - \$100,000 middle income, and those above this threshold as high-income.

450 ^c Diagnosed with any of the following: diabetes, cancer, heart disease, kidney disease,
451 asthma, chronic lung disease, an autoimmune disease.

452 * $P < .05$. ** $P < .01$. *** $P < .001$

Table 3. Attitudes Towards Vaccination against COVID-19 in the Understanding America Study assessed between October 14th and 31st 2020 (N = 5762).

Question ^b	Full sample		Willing to vaccinate ^a		Undecided on vaccination ^a		Unwilling to vaccinate ^a	
	Agree (%)	Disagree (%)	Agree (%)	Disagree (%)	Agree (%)	Disagree (%)	Agree (%)	Disagree (%)
1. The COVID vaccine will be important for my health.	71.2	28.8	93.8	6.2	69.1	30.9	33.7	66.3
2. Getting a COVID vaccine would be a good way to protect me from coronavirus disease.	74.2	25.8	95.4	4.6	71.6	28.4	39.3	60.7
3. The COVID vaccine will be effective if it is approved by the FDA or CDC.	73.7	26.3	92.4	7.6	71.0	29.0	43.1	56.9
4. Getting the COVID vaccine will be important for the health of others in my community.	79.4	20.6	96.1	3.9	77.7	22.3	51.7	48.3
5. The COVID vaccine will be beneficial to me.	73.8	26.2	95.1	4.9	74.3	25.7	37.4	62.6
6. I will do what my doctor or health care provider recommends about the COVID vaccine.	74.5	25.5	92.8	7.2	70.9	29.1	44.7	55.3
7. The COVID vaccine will not be around long enough to be sure it is safe.	48.1	51.9	39.9	60.1	58.8	41.2	57.3	42.7
8. I am concerned about serious side effects of the COVID vaccine.	69.7	30.3	60.6	39.4	81.4	18.6	80.2	19.8
9. I think the COVID vaccine might cause lasting health problems for me.	43.6	56.4	26.6	73.4	61.5	38.5	65.0	35.0

Note: Estimates are based on weighted data. ^aBased-on responses to the question “*How likely are you to get vaccinated for coronavirus once a vaccine is available to the public?*”. In this survey wave (responses between October 14-31, 2020) 54% of the sample were classified as ‘Willing to vaccinate’, 14% ‘Undecided’, and 32% ‘Unwilling to vaccinate’. ^b Each item was rated on a four-point scale with those responding ‘Somewhat’ or ‘Strongly’ agree are coded as ‘Agree’ and those responding ‘Somewhat’ or ‘Strongly’ disagree are coded as ‘Disagree’.




Figure 1. Change in vaccination intentions across 13 waves of the Understanding America Study conducted between April 1st and October 31st, 2020. Graph is based on an analysis of 78453 observations on 7547 participants. Estimates are predicted probabilities from marginal effects calculated after a multinomial logistic regression model adjusted for age, sex, race/ethnicity, household income, educational attainment, and the presence of pre-existing health conditions. 95% confidence intervals are presented in grey.

Table S1. Results of unadjusted multinomial logistic regression analyses examining the relative risk of being undecided or unwilling to vaccinate against COVID-19 in October compared to April, 2020.

Variable	Undecided on vaccination		Unwilling to vaccinate	
	RRR ^a	(95% CI)	RRR ^a	(95% CI)
Overall sample	1.82***	(1.62, 2.05)	2.29***	(2.11, 2.48)
Age group				
18-34	1.75***	(1.34, 2.27)	2.37***	(1.98, 2.84)
35-49	1.84***	(1.49, 2.27)	2.26***	(1.95, 2.62)
50-64	1.92***	(1.56, 2.35)	2.54***	(2.18, 2.95)
65+				
Sex				
Male	1.80***	(1.48, 2.18)	2.12***	(1.87, 2.41)
Female	1.90***	(1.64, 2.20)	2.48***	(2.23, 2.76)
Race/ethnicity				
White	1.97***	(1.72, 2.25)	2.32***	(2.12, 2.54)
Hispanic	1.89***	(1.32, 2.68)	2.52***	(2.00, 3.17)
Black	1.41*	(1.03, 1.92)	2.08***	(1.62, 2.67)
Other race/ ethnicity	3.49***	(1.94, 6.29)	2.70***	(1.79, 4.06)
Education				
Degree	1.71***	(1.32, 2.21)	2.09***	(1.82, 2.41)
No degree	2.01***	(1.75, 2.31)	2.52***	(2.28, 2.79)
Income level ^b				
Low income	2.01***	(1.70, 2.37)	2.53***	(2.20, 2.92)
Middle income	1.83***	(1.48, 2.25)	2.17***	(1.92, 2.46)
High income	1.70***	(1.18, 2.42)	2.31***	(1.93, 2.77)
Chronic condition ^c				
No	1.77***	(1.53, 2.05)	2.23***	(2.02, 2.46)
Yes	1.93***	(1.59, 2.34)	2.48***	(2.15, 2.86)

^a RRR = Relative risk ratio. For all analyses “willing to vaccinate” was the outcome reference group.

^b Households earning less than \$40,000 a year classified as low income, those earning \$40,000 - \$100,000 middle income, and those above this threshold as high-income.

^c Diagnosed with any of the following: diabetes, cancer, heart disease, kidney disease, asthma, chronic lung disease, an autoimmune disease.

* $P < .05$. ** $P < .01$. *** $P < .001$